There is a strong rationale for IFN-β gene therapy as a novel therapeutic approach for arthritis.
Answers are grounded in this paper and cite their sources.
No clinical adoption of IFN-β gene therapy yet; leaves open prospective trials to test efficacy in arthritis.
Margriet J Vervoordeldonk, Caroline J Aalbers & Paul P Tak† †Author for correspondence Academic Medical Center/University of Amsterdam, Division of Clinical Immunology and Rheumatology, F4–218, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands Tel.: +31 205 662 171; Fax: +31 206 919 658; p.p.tak@amc.uva.nl and, Arthrogen BV, Amsterdam, The Netherlands ‘[There is] a strong rationale for IFN-β gene therapy as a novel therapeutic approach for arthritis.’
No takes yet. Share an insight, caveat, or question.
Vervoordeldonk et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: